Pfizer Inc.

NYSE:PFE Rapport sur les actions

Capitalisation boursière : US$157.7b

Pfizer Dividendes et rachats

Dividende contrôle des critères 5/6

Pfizer est une société versant des dividendes avec un rendement actuel de 6.22%.

Informations clés

6.2%

Rendement du dividende

n/a

Rendement des rachats

Rendement total pour l'actionnairen/a
Rendement futur des dividendes6.3%
Croissance des dividendes4.1%
Prochaine date de paiement du dividenden/a
Date ex-dividenden/a
Dividende par actionn/a
Ratio de distribution226%

Mises à jour récentes sur les dividendes et les rachats

Recent updates

Mise à jour du récit • Sep 18

PFE: Acquired Growth Supports The Case, Pipeline Execution Still Sets The Ceiling

The Pfizer thesis has been reviewed and reaffirmed, with the updated narrative shifting the focus toward the contribution of acquired portfolios, cost savings programs, and the emerging obesity franchise as the key drivers of the story from here. What's Changed Focus previously sat on broad late stage pipeline expansion in oncology, rare disease and vaccines as the main growth driver.
Seeking Alpha • Sep 10

Pfizer: Firing On All Cylinders

Summary Pfizer remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield, with disciplined capital allocation. Key risks include margin pressure and Eliquis pricing reversals, but cost programs and pipeline momentum support the bullish thesis. Read the full article on Seeking Alpha
Mise à jour du récit • Aug 05

PFE: Pipeline Readouts And Legal Overhang Will Shape Post Covid Earnings Trajectory

The analyst fair value estimate for Pfizer has risen from $24.00 to $25.00 as analysts factor in updated pipeline expectations, modestly stronger profit margin assumptions, and recent Street price target moves that cluster in the mid to high $20s per share. Analyst Commentary Recent Street views on Pfizer sit in a fairly tight range in the mid to high US$20s, with most price targets clustered between US$25 and US$35.
Mise à jour du récit • Jul 13

PFE: Oncology And Obesity Pipeline Will Drive Post Patent Cliff Repricing

Pfizer's analyst price target has edged lower by about $0.80, reflecting updated models that factor in softer revenue expectations, slightly higher long term margin assumptions, and a reset of near term enthusiasm following multiple target cuts and a downgrade to Hold from several firms ahead of upcoming earnings catalysts. Analyst Commentary Recent research on Pfizer points to a mix of caution and optimism, with several firms trimming price targets while still seeing room for the stock to re-rate as execution on the core portfolio, business development and upcoming data readouts play through.
Mise à jour du récit • Jun 22

PFE: Oncology And Obesity Pipeline Progress Will Balance Patent Cliff Risks

Pfizer's analyst price target edges up by $1 to $26, as analysts point to a more balanced risk and reward profile supported by recent guidance commentary, oncology pipeline milestones, and updated views on longer term revenue and margin assumptions. Analyst Commentary Recent research coverage around Pfizer highlights a mix of upgraded ratings, modest price target increases and ongoing questions around specific product exposures and partnership choices.
Article d’analyse • Jun 20

Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions

Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...
Mise à jour du récit • Jun 08

PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing

Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
Mise à jour du récit • May 25

PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential

Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.
Mise à jour du récit • May 03

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook

Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.
Mise à jour du récit • Apr 19

PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing

Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.
Mise à jour du récit • Apr 05

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
Mise à jour du récit • Mar 22

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook

Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.
Mise à jour du récit • Mar 08

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade

Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.
Mise à jour du récit • Feb 21

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.
Mise à jour du récit • Feb 07

PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating

Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.
Mise à jour du récit • Jan 24

PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares

Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.
Mise à jour du récit • Jan 10

PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential

Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.
Article d’analyse • Jan 08

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...
Mise à jour du récit • Dec 25

PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead

Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.
Article d’analyse • Dec 18

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Les dividendes par action de PFE sont restés stables au cours des 10 dernières années.

Dividende croissant: Les paiements de dividendes de PFE ont augmenté au cours des 10 dernières années.

Rendement des dividendes par rapport au marché

Pfizer Rendement des dividendes par rapport au marché
Comment le rendement du dividende de PFE se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (PFE)6.2%
25% du marché (US)1.4%
25% du marché (US)4.2%
Moyenne du secteur (Pharmaceuticals)1.9%
Analyste prévisionnel (PFE) (jusqu'à 3 ans)6.3%

Dividende notable: Le dividende de PFE ( 6.22% ) est supérieur à celui des 25 % des payeurs de dividendes les plus faibles du marché US ( 1.38% ).

Dividende élevé: Le dividende de PFE ( 6.22% ) se situe dans les 25 % des premiers payeurs de dividendes du marché US ( 4.18% )

Bénéfice distribué aux actionnaires

Couverture des revenus: Avec son ratio de distribution élevé (225.6%), les paiements de dividendes de PFE ne sont pas bien couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Avec son taux de distribution en espèces actuel ( 89.2% ), les paiements de dividendes de PFE sont couverts par les flux de trésorerie.

Découvrir des entreprises qui versent des dividendes élevés

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/20 00:54
Cours de l'action en fin de journée2026/09/18 00:00
Les revenus2026/06/28
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Pfizer Inc. est couverte par 45 analystes. 25 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
David ToungArgus Research Company
Emily FieldBarclays
"Emily FieldBarclays